Clinical trial
An Open-label, Nonrandomized, Phase IIIb, Single Dose Study to Evaluated the Changes in Optical Coherence Tomography (OCT) and Fluorescein Angiography (FA) After Intravitreal Injection of Lucentis® in Patients With Macular Edema Secondary to Retinal Vein Occlusion (RVO)
NCT00942864 is registered in ClinicalTrials.gov with Novartis Korea Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label, Nonrandomized, Phase IIIb, Single Dose Study to Evaluated the Changes in Optical Coherence Tomography (OCT) and Fluorescein Angiography (FA) After Intravitreal Injection of Lucentis® in Patients With Macular Edema Secondary to Retinal Vein Occlusion (RVO)
- Lead sponsor
- Novartis Korea Ltd.
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- December 31, 2008
- Completion date
- December 31, 2009
- Enrollment
- 40 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.